Literature DB >> 10407077

Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties.

M J Fonseca1, H J Haisma, S Klaassen, M H Vingerhoeds, G Storm.   

Abstract

Immuno-enzymosomes have been proposed for the targeting of enzymes to cancer cells to achieve site specific activation of anticancer prodrugs. Previously, we reported that the enzyme beta-glucuronidase (GUS), capable of activating anthracycline-glucuronide prodrugs, can be coupled to the surface of inmunoliposomes directed against human ovarian cancer cells (OVCAR-3). This study aimed at the design of an immuno-enzymosome formulation with maximum enzyme targeting capability. By purification of the commercially available enzyme beta-glucuronidase (GUS), a 2-fold increase in the enzyme specific activity and a 4-fold increase in the enzymatic activity of immuno-enzymosomes was achieved. As a result, upon incubation with human ovarian cancer cells (OVCAR-3), cell-associated enzymatic activity increased correspondingly. The optimized immuno-enzymosomes were shown to bind to the target cells in a specific fashion. Above a GUS/Fab' molar ratio of 0.5, impairment of the target cell binding ability of the immuno-enzymosomes was observed. This was likely due to a steric hindrance effect mediated by the presence of large amounts of bulky GUS molecules on the liposome surface. Nevertheless, increasing the GUS density on the surface of the immuno-enzymosomes to levels by far exceeding the GUS/Fab' molar ratio of 0.5, yielded a considerably improved enzyme targeting capability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10407077     DOI: 10.1016/s0005-2736(99)00073-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.

Authors:  Amjad Ali Khan; Khaled S Allemailem; Saleh A Almatroodi; Ahmed Almatroudi; Arshad Husain Rahmani
Journal:  3 Biotech       Date:  2020-03-10       Impact factor: 2.406

2.  Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.

Authors:  María José Fonseca; Joycelyn C Jagtenberg; Hidde J Haisma; Gert Storm
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

3.  Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.

Authors:  James O Park; Zachary Stephen; Conroy Sun; Omid Veiseh; Forrest M Kievit; Chen Fang; Matthew Leung; Hyejung Mok; Miqin Zhang
Journal:  Mol Imaging       Date:  2011-02       Impact factor: 4.488

4.  Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery.

Authors:  Dinesh Kumar; Deepak Sharma; Gurmeet Singh; Mankaran Singh; Mahendra Singh Rathore
Journal:  ISRN Pharm       Date:  2012-07-19

5.  Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF.

Authors:  Zheng-jie Huang; Yilin Zhao; Wei-yuan Luo; Jun You; Shui-wen Li; Wen-cheng Yi; Sheng-yu Wang; Jiang-hua Yan; Qi Luo
Journal:  ScientificWorldJournal       Date:  2013-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.